BiVictriX strengthens its patent portfolio

RNS Number : 2007C

BiVictriX Therapeutics PLC

21 February 2022

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

BiVictriX strengthens its patent portfolio with filing of four new patents

Alderley Park, 2 1 February 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that it has filed four new patent applications in the UK related to several novel cancer-specific antigen pairs or "fingerprints" across a range of oncology indications.

The new patent applications focus on three novel cancer-specific antigen fingerprints that have been identified by the Company and can be used to support the development of a pipeline of highly selective, cancer therapeutics utilising the Company's proprietary Bi-Cygni® approach. This will further strengthen BiVictriX's growing intellectual property portfolio and provide opportunities to widen the application of the Company's Bi-Cygni® technology across several solid tumour and haematological cancers, demonstrating the broad utility of the approach. These filings are the next step in the Company's strategy to broaden its patent portfolio both in the UK and internationally.

BiVictriX's novel approach to cancer therapies relies on utilising its proprietary library of cancer-specific antigen co-expression fingerprints, or "twin antigens", which are uniquely expressed on a cancer. The Company's pipeline of Bi-Cygni® therapeutics are designed to selectively target these twin antigens which are present on tumour cells and largely absent from healthy cells, enabling the development of a novel class of next-generation anti-cancer therapies with potentially superior cancer selectivity and a significantly reduced side-effect profile. This approach has the potential to deliver better treatment outcomes for patients. 

Tiffany Thorn, Chief Executive Officer of BiVictriX, commented: "We are excited to be expanding our existing patent portfolio across a wider range of cancer types that currently constitute areas of high unmet medical need, demonstrating the broad utility of our innovative Bi-Cygni® platform. The new patents, if approved, will provide broad protection for our pipeline assets, allowing the development of several generations of cancer-selective Bi-Cygni® therapeutics across a wide range of solid tumour and haematological cancers that constitute areas of urgent unmet need. I look forward to providing further updates regarding the application for these new patents as appropriate."

The patent applications in BiVictriX's growing portfolio are wholly owned by BiVictriX and, as such, are not subject to any licensing arrangements.

ENDS

For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker) Tel: [phone] David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker) Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl Consilium Strategic Communications Mary-Jane Elliott, Genevieve Wilson, Alex Gunter Tel: [phone] Email:  [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at  www.bivictrix.com    

 

END

 

 

MSCBKCBNDBKDNBD